News

Teva posted a net income of $1.05bn for the third quarter 2010, or $1.15 per diluted share, compared to $649m, or $0.72 per diluted share, for the comparable

Reviewed by scientists at the Department of Health and Human Services, the research grant has been awarded to X-BODY for its human monoclonal antibody therapeutic project targeting metastatic

Depomed is a specialty pharmaceutical company with one product candidate through Phase 3 clinical development, another in Phase 3 clinical development, two approved products on the market and

The acquisition will allow Nycomed to gain access to a number of biologic and protein-based drugs manudactured by Techpool. Techpool has developed and launched a number of protein

Smith will replace Richard Friedman, who will be stepping down as CEO to serve as non-executive chairman of the BioScrip board of directors, effective 1 January 2011. Prior

Akorn has posted a net income of $3.99m for the third quarter 2010, or $0.04 per diluted share, compared to net loss of $5.1m, or $0.06 loss per

VGX-3100 is a therapeutic vaccine for cervical dysplasia and cancer. The grant will also support Inovio Pharma’s development projects for Syncon universal flu and dengue vaccines. The PPACA

Boehringer is expected to make available the 75mg dose of Pradaxa in pharmacies in the coming weeks. Pradaxa received approval from the US Food and Drug Administration (FDA)

The Talent Captivia System is indicated specifically for the endovascular repair of fusiform aneurysms and saccular aneurysms/penetrating ulcers of the descending thoracic aorta in patients having appropriate anatomy.